Cardiovascular Safety of Hydroxychloroquine-Azithromycin in 424 COVID-19 Patients

被引:2
|
作者
Million, Matthieu [1 ,2 ]
Lagier, Jean-Christophe [1 ,2 ]
Hourdain, Jerome [3 ,4 ]
Franceschi, Frederic [3 ,4 ]
Deharo, Jean-Claude [3 ,4 ]
Parola, Philippe [1 ,5 ]
Brouqui, Philippe [1 ,2 ]
机构
[1] IHU Mediterranee Infect, F-13005 Marseille, France
[2] Aix Marseille Univ, AP HM, Fac Sci Med & Paramed, Inst Rech Dev,Unite MEPHI Microbes Evolut Phylogen, F-13005 Marseille, France
[3] Ctr Hosp Univ Timone, AP HM, Serv Cardiol, F-13005 Marseille, France
[4] Aix Marseille Univ, Fac Sci Med & Paramed, C2VN, F-13005 Marseille, France
[5] Aix Marseille Univ, AP HM, Fac Sci Med & Paramed, VITROME,IRD, F-13005 Marseille, France
来源
MEDICINA-LITHUANIA | 2023年 / 59卷 / 05期
关键词
COVID-19; SARS-CoV-2; hydroxychloroquine; azithromycin; QTc interval; cardiac rhythm; safety; torsades de pointe; COMBINATION; THERAPY;
D O I
10.3390/medicina59050863
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: Hydroxychloroquine (HCQ) combined with azithromycin (AZM) has been widely administered to patients with COVID-19 despite scientific controversies. In particular, the potential of prolong cardiac repolarization when using this combination has been discussed. Materials and Methods: We report a pragmatic and simple safety approach which we implemented among the first patients treated for COVID-19 in our center in early 2020. Treatment contraindications were the presence of severe structural or electrical heart disease, baseline corrected QT interval (QTc) > 500 ms, hypokalemia, or other drugs prolonging QTc that could not be interrupted. Electrocardiogram and QTc was evaluated at admission and re-evaluated after 48 h of the initial prescription. Results: Among the 424 consecutive adult patients (mean age 46.3 +/- 16.1 years; 216 women), 21.5% patients were followed in conventional wards and 78.5% in a day-care unit. A total of 11 patients (2.6%) had contraindications to the HCQ-AZ combination. In the remaining 413 treated patients, there were no arrhythmic events in any patient during the 10-day treatment regimen. QTc was slightly but statistically significantly prolonged by 3.75 +/- 25.4 ms after 2 days of treatment (p = 0.003). QTc prolongation was particularly observed in female outpatients <65 years old without cardiovascular disease. Ten patients (2.4%) developed QTc prolongation > 60 ms, and none had QTc > 500 ms. Conclusions: This report does not aim to contribute to knowledge of the efficacy of treating COVID-19 with HCQ-AZ. However, it shows that a simple initial assessment of patient medical history, electrocardiogram (ECG), and kalemia identifies contraindicated patients and enables the safe treatment of COVID-19 patients with HCQ-AZ. QT-prolonging anti-infective drugs can be used safely in acute life-threatening infections, provided that a strict protocol and close collaboration between infectious disease specialists and rhythmologists are applied.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen
    Bernardini, Andrea
    Ciconte, Giuseppe
    Negro, Gabriele
    Rondine, Roberto
    Mecarocci, Valerio
    Viva, Tommaso
    Santini, Francesca
    de Innocentiis, Carlo
    Giannelli, Luigi
    Witkowska, Ewa
    Locati, Emanuela Teresina
    Castelvecchio, Serenella
    Marrocco-Trischitta, Massimiliano M.
    Vicedomini, Gabriele
    Menicanti, Lorenzo
    Pappone, Carlo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 324 : 242 - 248
  • [2] A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients
    Chowdhury, Abu Taiub Mohammed Mohiuddin
    Shahbaz, Mohammad
    Karim, Md Rezaul
    Islam, Jahirul
    Dan, Guo
    He, Shuixiang
    EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, 2021, 5 (01): : 63 - 70
  • [3] Hydroxychloroquine-azithromycin for COVID-19-Warranted or dangerous?
    Popescu, Corneliu P.
    Fischer, Philip R.
    TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2020, 35
  • [4] Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients
    Gautret, Philippe
    Honore, Stephane
    Lagier, Jean-Christophe
    Raoult, Didier
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (01)
  • [5] Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection
    Voisin, Olivier
    le Lorc'h, Erwan
    Mahe, Annabelle
    Azria, Philippe
    Borie, Marie-Francoise
    Hubert, Sidonie
    Menage, Elodie
    Guillerm, Jean-Christophe
    Mourad, Jean-Jacques
    MAYO CLINIC PROCEEDINGS, 2020, 95 (08) : 1696 - 1700
  • [6] Hydroxychloroquine versus hydroxychloroquine-azithromycin combination therapy on QT interval prolongation of COVID-19 patients: a systematic review and meta-analysis
    Pinandito, Yohanes Krisnantyo Adi
    Salfi, Qorina Nadya
    Putri, Kezia Warokka
    Caesario, Jefferson
    Rahmadi, I. Gusti Hanif
    Suhargo, Melisa
    Rafikasari, Aulia
    Julario, Rerdin
    Prajitno, Subur
    COR ET VASA, 2021, 63 (04) : 475 - 480
  • [7] Cardiovascular safety of hydroxychloroquine in the COVID-19 pandemic
    Bozzo, Raul
    Ibelli, Fabiana
    Scublinsky, Dario
    MEDICINA-BUENOS AIRES, 2020, 80 : 89 - 90
  • [8] Hydroxychloroquine with or without Azithromycin in Covid-19
    Choudhary, Rahul
    Bohra, Gopal K.
    Kumar, Deepak
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (02): : 190 - 191
  • [9] Hydroxychloroquine and azithromycin as a treatment of COVID-19
    Alice Fanin
    Jessica Calegari
    Anna Beverina
    Silvia Tiraboschi
    Internal and Emergency Medicine, 2020, 15 : 841 - 843
  • [10] Hydroxychloroquine and azithromycin as a treatment of COVID-19
    Fanin, Alice
    Calegari, Jessica
    Beverina, Anna
    Tiraboschi, Silvia
    INTERNAL AND EMERGENCY MEDICINE, 2020, 15 (05) : 841 - 843